J&J’s Dual CAR-T Shows Promise in Large B-cell Lymphoma
June 13, 2025
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease Johnson
